Biomedical Politics.

Mostrar otras versiones (1)
Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Staff, Institute of Medicine
Otros Autores: Hanna, Kathi E.
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Washington : National Academies Press, 1991.
Colección:Online access: National Academy of Sciences National Academies Press.
Online access: NCBI NCBI Bookshelf.
Temas:
Medical policy > Case studies.
Health planning > Case studies.
Politique sanitaire > Études de cas.
Santé publique > Planification > Études de cas.
Health planning
Medical policy
Case studies
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Biomedical Politics
  • Copyright
  • Preface
  • Acknowledgments
  • Contents
  • Introduction
  • References
  • Unproven AIDS Therapies: The Food and Drug Administration and DDI
  • THE DRUG REGULATION PROCESS
  • The Drug Approval Process Today
  • Speeding Up the Process: The Bush Initiative
  • Prelicensing Availability
  • PARALLEL TRACK
  • PARALLEL TRACK: PROS AND CONS
  • The Food and Drug Administration
  • The Research Community
  • The AIDS Activists
  • Other Consumer Interests
  • EARLY RELEASE OF DDI
  • MOTIVATIONS
  • Bristol-Myers
  • The Food and Drug AdministrationThe National Institutes of Health
  • The Activists
  • CONCLUSIONS
  • NOTES
  • REFERENCES
  • Commentary
  • LEON EISENBERG
  • Commentary
  • PETER F. CARPENTER
  • A Political History of RU-486
  • Introducing Contraceptives to the United States
  • THE EARLY DEVELOPMENT OF RU-486
  • COMMERCIAL INTEREST IN RU-486
  • THE GROWING THREAT OF ANTI-ABORTION GROUPS
  • CORPORATE PRESSURE FOR WITHDRAWAL
  • THE RETURN OF RU-486
  • THE CONTINUING OPPOSITION
  • SUCCESS OF THE BOYCOTT THREAT
  • THE FEMINIST AND MEDICAL COMMUNITY RESPONSEINTERNATIONAL RU-486 AVAILABILITY
  • GETTING RU-486 TO THE UNITED STATES
  • INDUSTRY CONSTRAINTS ON RU-486 DEVELOPMENT
  • Market Share and Price
  • FDA Review
  • Product Liability
  • Public Relations
  • AMERICAN ACCESS TO RU-486 IN THE 1990S
  • REFERENCES
  • Commentary
  • WILLIAM N. HUBBARD
  • Commentary
  • PETER F. CARPENTER
  • The Human Genome Project: The Formation of Federal Policies in the United States, 1986â€?1990
  • TECHNICAL AND SCIENTIFIC BACKGROUND
  • ORIGINS OF DEDICATED GENOME RESEARCH PROGRAMS
  • THE DEPARTMENT OF ENERGY PLANTHE SCIENTIFIC COMMUNITY RESPONDS
  • CALLS FOR EVALUATION
  • THE NATIONAL INSTITUTES OF HEALTH AND CONGRESS RESPOND
  • THE PROJECT IS FUNDED
  • SOCIAL ISSUES EMERGE
  • STILL, ORGANIZATIONAL ISSUES
  • CONCLUSIONS
  • APPENDIX A
  • Where Was OSTP?
  • APPENDIX B
  • Can the Genome Project Keep Its Promises?
  • APPENDIX C
  • Is Cost Wobble a Serious Problem?
  • APPENDIX D
  • What Is Technically Feasible in the Policy Context?
  • REFERENCES
  • Commentary
  • PAUL BERG
  • Commentary
  • ERNEST R. MAY
  • Origins of the Medicare Kidney Disease Entitlement: The Social Security Amendments of 1972A HISTORICAL FOOTNOTE
  • ANTECEDENTS TO THE 1972 LEGISLATION
  • The Influence of the Gottschalk Report
  • Setting the Legislative Stage
  • THE SOCIAL SECURITY AMENDMENTS OF 1972, SECTION 299I
  • The Legislative Process
  • The Policy Context
  • The Adoption of Section 299I
  • Ways and Means: November and December 1971
  • Senate Finance Committee: 1972
  • The Joint House-Senate Conference Committee: 1972
  • ESTIMATES OF COST
  • SUMMARY AND CONCLUSIONS
  • AFTERWORD

Ejemplares similares